// ============================================================
// PULSAR V15 â€” TPE Engine (Therapeutic Prospection Engine)
// Moteur prÃ©dictif â€” Le traitement de demain
// Croise les donnÃ©es inter-pathologies pour gÃ©nÃ©rer des hypothÃ¨ses
// Couleur identitaire : #FFB347 (ambre dorÃ©)
// ============================================================

import { BrainCore, SemanticField } from './BrainCore'
import {
  PatientState, IntentionResult, ContextResult, RuleResult,
  CurveResult, SynthesisResult, TherapeuticHypothesis,
} from './PatientState'

export class TPEEngine extends BrainCore {
  private hypothesesBank: TherapeuticHypothesis[]

  constructor() {
    super('TPE')

    // â”€â”€ Banque d'hypothÃ¨ses thÃ©rapeutiques â”€â”€
    // Construite Ã  partir des croisements inter-pathologies et littÃ©rature Ã©mergente
    this.hypothesesBank = [
      {
        id: 'H1_ANAKINRA_FIRES_IL1',
        title: 'Anakinra prÃ©coce dans le FIRES Ã  profil IL-1Î²',
        rationale: 'L\'hypothÃ¨se inflammasome NLRP3/IL-1Î² (Lin & Hsu 2021) suggÃ¨re que le FIRES est un syndrome auto-inflammatoire. L\'anakinra (antagoniste IL-1R) a montrÃ© une rÃ©duction des crises chez >50% des patients (Costagliola 2022, 37 patients). L\'initiation PRÃ‰COCE (avant J5) pourrait prÃ©venir les sÃ©quelles irrÃ©versibles.',
        mechanismOfAction: 'Blocage du rÃ©cepteur IL-1 â†’ inhibition de la cascade inflammasome NLRP3 â†’ rÃ©duction de la neuro-inflammation et de l\'excitotoxicitÃ© glutamatergique',
        supportingEvidence: ['Lin & Hsu, Clin Transl Immunol 2021 (hypothÃ¨se NLRP3)', 'Costagliola et al., Front Neurol 2022 (37 patients, >50% rÃ©ponse)', 'Shrestha et al., Front Neurol 2023 (6 patients pÃ©d, rÃ©duction crises)', 'Clarkson et al., Ann Neurol 2019 (dÃ©ficit endogÃ¨ne IL-1Ra dans FIRES)'],
        confidenceLevel: 'emerging',
        targetPathway: 'IL-1Î² / Inflammasome NLRP3',
        applicablePathologies: ['FIRES', 'NORSE'],
      },
      {
        id: 'H2_TOCILIZUMAB_CROSS',
        title: 'Tocilizumab pour FIRES Ã  profil IL-6 Ã©levÃ© (croisement PIMS)',
        rationale: 'Le tocilizumab (anti-IL-6R) est efficace dans le PIMS/MIS-C. Kothur et al. ont montrÃ© des Ã©lÃ©vations IL-6 dans le LCR de patients FIRES. Si un patient FIRES prÃ©sente un profil cytokinique dominÃ© par l\'IL-6 plutÃ´t que l\'IL-1Î², le tocilizumab pourrait Ãªtre plus adaptÃ© que l\'anakinra.',
        mechanismOfAction: 'Blocage du rÃ©cepteur IL-6 â†’ inhibition de la signalisation JAK/STAT â†’ rÃ©duction de la cascade inflammatoire systÃ©mique et neurologique',
        supportingEvidence: ['Kothur et al., Cytokine 2016 (IL-6 Ã©levÃ©e dans LCR FIRES)', 'Feldstein NEJM 2020 (efficacitÃ© tocilizumab dans PIMS)', 'Costagliola et al. 2022 (anti-cytokiniques dans Ã©pilepsie)'],
        confidenceLevel: 'exploratory',
        targetPathway: 'IL-6 / JAK-STAT',
        applicablePathologies: ['FIRES', 'PIMS/MIS-C'],
      },
      {
        id: 'H3_RITUXIMAB_MOGAD_EARLY',
        title: 'Rituximab prÃ©coce dans MOGAD rÃ©cidivant pÃ©diatrique',
        rationale: 'Les donnÃ©es Bilodeau 2024 et Banwell 2023 montrent un taux de rechute Ã©levÃ© dans le MOGAD pÃ©diatrique. L\'initiation prÃ©coce du rituximab (sans passer par cyclophosphamide, CI dans MOGAD) pourrait rÃ©duire les rechutes et les sÃ©quelles visuelles.',
        mechanismOfAction: 'DÃ©plÃ©tion des lymphocytes B CD20+ â†’ rÃ©duction de la production d\'anticorps anti-MOG pathogÃ¨nes â†’ prÃ©vention des poussÃ©es dÃ©myÃ©linisantes',
        supportingEvidence: ['Banwell et al., Lancet Neurol 2023 (critÃ¨res MOGAD)', 'Bilodeau et al. 2024 (outcomes thÃ©rapeutiques)', 'Kurd 2024 (sÃ©ries pÃ©diatriques europÃ©ennes)'],
        confidenceLevel: 'supported',
        targetPathway: 'Lymphocytes B / Anti-MOG',
        applicablePathologies: ['MOGAD/ADEM'],
      },
      {
        id: 'H4_KETOGENIC_NEUROPROTECTION',
        title: 'RÃ©gime cÃ©togÃ¨ne comme neuroprotecteur prÃ©coce dans FIRES',
        rationale: 'Le rÃ©gime cÃ©togÃ¨ne est utilisÃ© en L2 dans le FIRES mais souvent tardivement. Les donnÃ©es prÃ©cliniques et les sÃ©ries de cas (van Baalen 2023) suggÃ¨rent un effet neuroprotecteur indÃ©pendant de l\'effet antiÃ©pileptique, via la rÃ©duction du stress oxydatif et la modulation de l\'inflammasome.',
        mechanismOfAction: 'Production de corps cÃ©toniques â†’ substrat Ã©nergÃ©tique alternatif neuronal + inhibition NLRP3 + rÃ©duction ROS + stabilisation GABAergique',
        supportingEvidence: ['Van Baalen 2023 (approche pratique FIRES)', 'Gofshteyn et al., J Child Neurol 2017 (rÃ©gime cÃ©togÃ¨ne FIRES)'],
        confidenceLevel: 'emerging',
        targetPathway: 'MÃ©tabolisme cÃ©togÃ¨ne / NLRP3',
        applicablePathologies: ['FIRES', 'NORSE'],
      },
      {
        id: 'H5_COMBINED_ANTI_CYTOKINE',
        title: 'Double blocage cytokinique IL-1Î² + IL-6 dans l\'orage rÃ©fractaire',
        rationale: 'Dans les cas de FIRES avec orage cytokinique rÃ©fractaire au traitement unique, le croisement avec les protocoles MAS/PIMS suggÃ¨re qu\'un double blocage (anakinra + tocilizumab) pourrait Ãªtre envisagÃ©, Ã  l\'image des protocoles rhumatologiques pour le MAS rÃ©fractaire.',
        mechanismOfAction: 'Blocage simultanÃ© des deux axes inflammatoires majeurs â†’ suppression large de la cascade cytokinique â†’ effet synergique anti-inflammatoire',
        supportingEvidence: ['Lin & Hsu 2021 (NLRP3/IL-1Î²)', 'Kothur et al. 2016 (IL-6 dans LCR)', 'Protocoles MAS rhumatologiques (double blocage)'],
        confidenceLevel: 'exploratory',
        targetPathway: 'IL-1Î² + IL-6 dual',
        applicablePathologies: ['FIRES', 'NORSE', 'PIMS/MIS-C'],
      },
      {
        id: 'H6_PIMS_NEURO_SCREENING',
        title: 'Screening neurologique systÃ©matique dans PIMS/MIS-C',
        rationale: 'L\'Ã©tude Francoeur JAMA 2024 (3568 patients, 46 centres) montre que l\'atteinte neurologique PIMS est sous-diagnostiquÃ©e (8.5-32.1%) avec des sÃ©quelles Ã  la sortie (OR 1.85-2.18). Un screening EEG + IRM systÃ©matique Ã  l\'admission PIMS pourrait identifier les patients Ã  risque neuro.',
        mechanismOfAction: 'DÃ©tection prÃ©coce de l\'atteinte neuro-inflammatoire PIMS â†’ initiation ciblÃ©e de neuroprotection â†’ rÃ©duction des sÃ©quelles neurocognitives',
        supportingEvidence: ['Francoeur et al., JAMA Network Open 2024 (3568 pts, OR 1.85/2.18)', 'Feldstein NEJM 2020 (atteinte multi-organe PIMS)'],
        confidenceLevel: 'supported',
        targetPathway: 'Screening / DÃ©tection prÃ©coce',
        applicablePathologies: ['PIMS/MIS-C'],
      },
    ]

    // â”€â”€ Champ 1 : Profil cytokinique â”€â”€
    this.semanticFields.push(new SemanticField({
      name: 'Profil cytokinique', category: 'cytokine_profile', color: '#FFB347',
      signals: [
        { name: 'CRP comme proxy IL-6', weight: 2, extract: ps => ps.biology.crp, normalize: v => Math.min(100, (v as number) / 2) },
        { name: 'Ferritine comme proxy activation macrophagique', weight: 2, extract: ps => ps.biology.ferritin, normalize: v => { const n = v as number; return n >= 1000 ? 100 : n >= 500 ? 70 : n >= 200 ? 40 : n >= 100 ? 15 : 0 } },
        { name: 'IL-6 directe', weight: 3, extract: ps => ps.cytokines?.il6, normalize: v => v == null ? 0 : Math.min(100, (v as number) / 10) },
        { name: 'IL-1Î² directe', weight: 3, extract: ps => ps.cytokines?.il1b, normalize: v => v == null ? 0 : Math.min(100, (v as number) / 5) },
      ],
    }))

    // â”€â”€ Champ 2 : RÃ©ponse aux traitements actuels â”€â”€
    this.semanticFields.push(new SemanticField({
      name: 'RÃ©sistance thÃ©rapeutique', category: 'resistance', color: '#D63C3C',
      signals: [
        { name: 'Ã‰checs cumulÃ©s', weight: 3, extract: ps => ps.treatmentHistory.filter(t => t.response === 'none').length, normalize: v => Math.min(100, (v as number) * 30) },
        { name: 'DurÃ©e sans amÃ©lioration', weight: 2, extract: ps => ps.hospDay, normalize: v => Math.min(100, (v as number) * 8) },
        { name: 'RÃ©ponses partielles', weight: 1.5, extract: ps => ps.treatmentHistory.filter(t => t.response === 'partial').length, normalize: v => Math.min(80, (v as number) * 20) },
      ],
    }))

    // â”€â”€ Patterns TPE â”€â”€
    this.patterns.push({
      name: 'Profil IL-1Î² dominant',
      match: (ps) => {
        // FIRES classique + ferritine Ã©levÃ©e + pas d'Ac spÃ©cifiques
        const firesLike = ps.neuro.seizureType === 'refractory_status' || ps.neuro.seizureType === 'super_refractory'
        const highFerritin = ps.biology.ferritin > 500
        const noAb = ps.csf.antibodies === 'negative' || ps.csf.antibodies === 'pending'
        const il1High = (ps.cytokines?.il1b ?? 0) > 10
        if ((firesLike && highFerritin && noAb) || il1High) {
          return { confidence: il1High ? 0.9 : 0.65, description: 'Profil inflammasome NLRP3/IL-1Î²', implications: 'HypothÃ¨se anakinra prÃ©coce â€” Lin & Hsu 2021' }
        }
        return { confidence: 0, description: '', implications: '' }
      },
    })

    this.patterns.push({
      name: 'Profil IL-6 dominant (croisement PIMS)',
      match: (ps) => {
        const highCRP = ps.biology.crp > 100
        const il6High = (ps.cytokines?.il6 ?? 0) > 50
        const pimsFeatures = ps.pims.confirmed || ps.pims.cardiacInvolvement
        if (il6High || (highCRP && pimsFeatures)) {
          return { confidence: il6High ? 0.85 : 0.55, description: 'Axe IL-6/JAK-STAT prÃ©dominant', implications: 'HypothÃ¨se tocilizumab â€” croisement donnÃ©es PIMS' }
        }
        return { confidence: 0, description: '', implications: '' }
      },
    })

    this.patterns.push({
      name: 'RÃ©sistance multi-lignes',
      match: (ps) => {
        const fails = ps.treatmentHistory.filter(t => t.response === 'none')
        if (fails.length >= 2) return { confidence: Math.min(1, fails.length / 3), description: `${fails.length} Ã©checs â€” rÃ©sistance thÃ©rapeutique`, implications: 'Explorer hypothÃ¨ses non conventionnelles' }
        return { confidence: 0, description: '', implications: '' }
      },
    })

    // â”€â”€ RÃ¨gles TPE â”€â”€
    this.rules.push({
      name: 'Disclaimer Ã©thique', reference: 'PULSAR â€” Cadre dÃ©ontologique',
      evaluate: () => ({
        triggered: true,
        type: 'validation' as const,
        message: 'Les hypothÃ¨ses TPE sont des pistes de recherche, PAS des prescriptions. Discussion obligatoire en RCP avant toute application.',
      }),
    })
  }

  // â”€â”€ Couche 2 : Contexte TPE â”€â”€
  analyzeContext(ps: PatientState, ir: IntentionResult): ContextResult {
    const details: { type: string; label: string; detail: string; icon: string }[] = []
    let cm = 1.0

    // Plus le patient rÃ©siste aux traitements, plus les hypothÃ¨ses sont pertinentes
    const fails = ps.treatmentHistory.filter(t => t.response === 'none').length
    if (fails >= 2) { details.push({ type: 'multi_failure', label: 'RÃ©sistance multi-lignes', detail: `${fails} Ã©checs`, icon: 'ðŸ”¬' }); cm = 1.3 }

    // Lit les rÃ©sultats des 4 autres moteurs
    if (ps.vpsResult && ps.vpsResult.synthesis.score >= 60) {
      details.push({ type: 'high_severity', label: 'SÃ©vÃ©ritÃ© Ã©levÃ©e', detail: `VPS ${ps.vpsResult.synthesis.score}`, icon: 'ðŸ”´' })
      cm = Math.max(cm, 1.2)
    }

    if (ps.eweResult && ps.eweResult.synthesis.score >= 40) {
      details.push({ type: 'ewe_alert', label: 'Alerte prÃ©coce active', detail: `EWE ${ps.eweResult.synthesis.score}`, icon: 'âš¡' })
      cm = Math.max(cm, 1.15)
    }

    return { trend: details[0]?.type || 'stable', details, contextModifier: cm }
  }

  // â”€â”€ Couche 4 : Courbe â”€â”€
  computeCurve(ps: PatientState): CurveResult {
    const fails = ps.treatmentHistory.filter(t => t.response === 'none').length
    const partials = ps.treatmentHistory.filter(t => t.response === 'partial').length
    const data = [fails * 30, (fails + partials) * 20, Math.min(100, fails * 30 + ps.hospDay * 5)]
    return {
      trajectory: data, currentPosition: data.length - 1, currentValue: data[data.length - 1] || 0,
      globalIntensity: data[data.length - 1] || 0, trend: fails >= 2 ? 'exploration_needed' : 'conventional',
      curveData: data, labels: ['Ã‰checs', 'RÃ©sistance', 'Score global'],
    }
  }

  // â”€â”€ SÃ©lection des hypothÃ¨ses pertinentes â”€â”€
  private selectHypotheses(ps: PatientState, intention: IntentionResult): TherapeuticHypothesis[] {
    const selected: TherapeuticHypothesis[] = []

    for (const hyp of this.hypothesesBank) {
      let relevance = 0

      // Check pathology match â€” Ã©largi aux marqueurs biologiques
      const detectedPathologies: string[] = []
      if (ps.neuro.seizureType === 'refractory_status' || ps.neuro.seizureType === 'super_refractory') detectedPathologies.push('FIRES', 'NORSE')
      // Orage cytokinique avec crises = profil FIRES-like mÃªme sans SE rÃ©fractaire
      if (ps.biology.ferritin > 500 && ps.neuro.seizures24h >= 3) detectedPathologies.push('FIRES', 'NORSE')
      if (ps.csf.antibodies === 'nmdar') detectedPathologies.push('anti-NMDAR')
      if (ps.csf.antibodies === 'mog' || ps.mogad.mogAntibody) detectedPathologies.push('MOGAD/ADEM')
      if (ps.pims.confirmed || ps.pims.covidExposure) detectedPathologies.push('PIMS/MIS-C')

      const pathologyMatch = hyp.applicablePathologies.some(p => detectedPathologies.includes(p))
      if (pathologyMatch) relevance += 30

      // Check pattern match
      const il1Pattern = intention.patterns.find(p => p.name.includes('IL-1'))
      const il6Pattern = intention.patterns.find(p => p.name.includes('IL-6'))
      if (il1Pattern && hyp.targetPathway.includes('IL-1')) relevance += 40
      if (il6Pattern && hyp.targetPathway.includes('IL-6')) relevance += 40

      // Check resistance
      const fails = ps.treatmentHistory.filter(t => t.response === 'none').length
      if (fails >= 2) relevance += 20

      // Confidence boost
      if (hyp.confidenceLevel === 'supported') relevance += 10
      if (hyp.confidenceLevel === 'emerging') relevance += 5

      if (relevance >= 30) selected.push(hyp)
    }

    return selected.slice(0, 4) // Max 4 hypotheses
  }

  // â”€â”€ SynthÃ¨se TPE â”€â”€
  synthesize(ps: PatientState, intention: IntentionResult, context: ContextResult, rules: RuleResult[], curve: CurveResult): SynthesisResult {
    const resistance = intention.fields.find(f => f.category === 'resistance')?.intensity || 0
    const cytokine = intention.fields.find(f => f.category === 'cytokine_profile')?.intensity || 0
    let score = Math.min(100, Math.round((resistance * 0.5 + cytokine * 0.5) * context.contextModifier))

    const hypotheses = this.selectHypotheses(ps, intention)

    const alerts: PatientState['alerts'] = []
    const recs: PatientState['recommendations'] = []

    if (hypotheses.length > 0) {
      alerts.push({ severity: 'info', title: `${hypotheses.length} hypothÃ¨se(s) thÃ©rapeutique(s) identifiÃ©e(s)`, body: hypotheses.map(h => h.title).join(' Â· '), source: 'TPE' })
      hypotheses.forEach(h => {
        recs.push({
          priority: h.confidenceLevel === 'supported' ? 'medium' : 'low',
          title: `ðŸ’¡ ${h.title}`,
          body: h.rationale.substring(0, 200) + '...',
          reference: h.supportingEvidence[0],
        })
      })
    }

    let level: string
    if (score >= 70) level = 'EXPLORATION URGENTE'
    else if (score >= 50) level = 'EXPLORATION RECOMMANDÃ‰E'
    else if (score >= 25) level = 'HYPOTHÃˆSES DISPONIBLES'
    else level = 'TRAITEMENT CONVENTIONNEL'

    // Extend synthesis with hypotheses
    return { score, level, alerts, recommendations: recs }
  }
}
